Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). The company is focused on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease, a growing area with high unmet medical need.
Umecrine Cognition
Hepatic Encephalopathy is a significant and increasing health care problem due to the large and increasing epidemics of chronic liver disease.
